The mean and the biological variation of insulin resistance does not differ between polycystic ovary syndrome and type 2 diabetes

Annals of Clinical Biochemistry

Volumn 46, Issue 3, 2009, Pages 218-221

  Li, Wei Cho ^a,d   Jayagopal, V ^b   Kilpatrick, E S ^c   Atkin, S L ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b YORK HOSPITAL   (United Kingdom)

^c HULL ROYAL INFIRMARY   (United Kingdom)

^d Centre for Diabetes and Endocrinology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PANCREAS ISLET BETA CELL; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL;

ADULT; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME;

EID: 66249148380     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/acb.2008.008146     Document Type: Article

References (23)

1. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-146 (Pubitemid 29028311)
2. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800 (Pubitemid 28009567)
3. Reaven GM, Banting lecture. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607
4. Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL. The biological variation of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 2002;87:1560-1562 (Pubitemid 34615239)
5. Jayagopal V, Kilpatrick ES, Jennings PE, Hepburn DA, Atkin SL. Biological variation of homeostasis model assessment-derived insulin resistance in type 2 diabetes. Diabetes Care 2002;25:2022-2025 (Pubitemid 41071062)
6. ESHRE/ASRM-Sponsored-PCOS-Consensus-Workshop-Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25
7. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419 (Pubitemid 15018832)
8. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998;21:2191-2192 (Pubitemid 28549174)
9. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409-437
10. Gowans EM, Fraser CG. Biological variation of serum and urine creatinine and creatinine clearance: ramifications for interpretation of results and patient care. Ann Clin Biochem 1988;25:259-263 (Pubitemid 18157274)
11. Gungor N, Bacha F, Saad R, Janosky J, Arslanian S. Youth type 2 diabetes: insulin resistance, beta-cell failure, or both? Diabetes Care 2005;28:638-644
12. Lewy VD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr 2001;138:38-44 (Pubitemid 32097139)
13. Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab 2001;86:66-71 (Pubitemid 32109777)
14. Saely CH, Aczel S, Marte T, et al. The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 2005;90:5698-5703 (Pubitemid 41415478)
15. Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002;87:2013-2017 (Pubitemid 34521483)
16. Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 1997;126:32-35 (Pubitemid 27021216)
17. Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 2005;90:5711-5716 (Pubitemid 41415480)
18. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000;52:595-600 (Pubitemid 30337085)
19. Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb) 2000;3:101-105
20. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. Jama 2006;295:1681-1687
21. Stout RW. Insulin and atheroma. 20-yr perspective. Diabetes Care 1990;13:631-654
22. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991;34:416-422
23. Aguirre MA, Jones CN, Pei D, Villa ML, Reaven GM. Ethnic differences in insulin resistance and its consequences in older Mexican American and non-Hispanic white women. J Gerontol A Biol Sci Med Sci 1997;52:M56-60 (Pubitemid 27034831)